Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Radioligand

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Radioligand. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-003266-21 Sponsor Protocol Number: PSY-NIL-0012 Start Date*: 2023-03-31
    Sponsor Name:Medical University of Vienna
    Full Title: Acute effects of ketamine on the glutamatergic NMDA receptor quantified by PET and the radioligand (R)-[11C]-Me-NB1
    Medical condition: Acute effects of ketamine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004991-16 Sponsor Protocol Number: tba Start Date*: 2022-09-28
    Sponsor Name:
    Full Title: 177Lu-PSMA RADIOLIGAND THERAPY IN PATIENTS WITH LYMPH NODE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE D...
    Medical condition: prostate cancer, eligible for radical prostatectomy and extended pelvic lymph node dissection, with 1-3 pelvic nodal metastases on preoperative PSMA PET
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002677-24 Sponsor Protocol Number: self sponsored Start Date*: 2005-03-07
    Sponsor Name:Karolinska Institutet, Institutionen för klinisik neurovetenskap, sektion för psykiatri
    Full Title: Hormonersättningseffekt på serotoninåterupptag hos ooforektomerade kvinnor
    Medical condition: Bilateral oophorectomy and hysterectomy and a wish for hormonal replacement therapy afterwards.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003622-16 Sponsor Protocol Number: T214/2016 Start Date*: 2017-09-19
    Sponsor Name:Turku University Hospital
    Full Title: Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003713-11 Sponsor Protocol Number: 1938/2022 Start Date*: 2023-11-17
    Sponsor Name:Medical University of Vienna [...]
    1. Medical University of Vienna
    2. Medical University of Vienna
    Full Title: [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurrence after primary therapy with curative intent: A Prospec...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005305-19 Sponsor Protocol Number: D5130C00030 Start Date*: 2008-11-17
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previuosly Identified as Cl...
    Medical condition: Stable Coronary Artery Disease AZD6140 is under development for the prevention of thrombotic events in patients with non-ST and ST elevation coronary syndromes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003461-96 Sponsor Protocol Number: AGO/2017/006 Start Date*: 2017-12-21
    Sponsor Name:Ghent University Hospital
    Full Title: PSMA-PET/CT for prostate cancer
    Medical condition: prostate cancer (and metastases)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003857-27 Sponsor Protocol Number: LUPSA Start Date*: 2020-01-23
    Sponsor Name:Radboudumc
    Full Title: 177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study.
    Medical condition: Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002948-14 Sponsor Protocol Number: SC-FET15 Start Date*: 2015-09-22
    Sponsor Name:PET Diagnosztikai Kft.
    Full Title: Application of a new radioligand F-18 FET, and its clinical benefit in the diagnosis of primary and secondary brain tumors
    Medical condition: Primary and secondary brain tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-004115-92 Sponsor Protocol Number: 1944/2022 Start Date*: 2023-11-14
    Sponsor Name:Medical University of Vienna
    Full Title: Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging followed by radical prostatectomy: A Pros...
    Medical condition: Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2021-003478-30 Sponsor Protocol Number: CAAA802A12101 Start Date*: 2022-08-15
    Sponsor Name:Novartis Pharma AG
    Full Title: SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with heavily pre-treated PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) with or without...
    Medical condition: PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004803-19 Sponsor Protocol Number: D0490C00004 Start Date*: 2012-02-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Pos...
    Medical condition: Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-004979-19 Sponsor Protocol Number: EK Reg.-Nr. 040-2007 Start Date*: 2009-01-08
    Sponsor Name:University of Leipzig
    Full Title: In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET)
    Medical condition: To test a diagnostic imaging tool for specifically assessing the nicotinic acetylcholine receptor in vivo in patients with neurodegenerative diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003072-12 Sponsor Protocol Number: 01082018 Start Date*: 2019-02-05
    Sponsor Name:rigshospitalet
    Full Title: Radiation Therapy Planning by Multi-parametric PET/MRI Imaging in patients with cervical cancer
    Medical condition: cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008229 Cervical cancer LLT
    20.0 100000004864 10008233 Cervical cancer stage I LLT
    20.0 100000004864 10008234 Cervical cancer stage II LLT
    20.0 100000004864 10008235 Cervical cancer stage III LLT
    20.0 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000502-19 Sponsor Protocol Number: PSY-NIL-0002 Start Date*: 2016-06-21
    Sponsor Name:Medical University of Vienna, Department of Psychiatry and Psychotherapy
    Full Title: Effects of sex steroid hormones on serotonin synthesis and degradation measured with PET
    Medical condition: Gender Dysphoria (Female-to-male transsexuals and male-to-female transsexuals)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002512-14 Sponsor Protocol Number: AK2017-2 Start Date*: 2017-09-04
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002312-13 Sponsor Protocol Number: AK2017-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001550-42 Sponsor Protocol Number: 1.8_20190705 Start Date*: 2014-06-17
    Sponsor Name:Medizinische Universität Wien
    Full Title: Patient stratification and treatment response prediction in neuropharmacotherapy using PET/MR – Predicting drug efficacy using hybrid PET/MR imaging with pharmacological challenge and multirecepto...
    Medical condition: Major depressive disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000076-37 Sponsor Protocol Number: NL72585.091.20 Start Date*: 2023-03-30
    Sponsor Name:Radboud University Medical Center
    Full Title: Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.
    Medical condition: Oligo-metastatic adenocarcinoma of the prostate.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001960-31 Sponsor Protocol Number: 142/2019 Start Date*: 2019-08-27
    Sponsor Name:Turku PET centre
    Full Title: Effect of cladribine treatment on microglial activation in the CNS
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 05 04:39:42 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA